Can Abilify Cause SVT?
Aripiprazole (Abilify) is not documented to cause supraventricular tachycardia (SVT) specifically, but it can cause other cardiac arrhythmias including atrial fibrillation and tachycardia, particularly in overdose situations or in patients with risk factors.
Cardiac Effects of Aripiprazole
The FDA drug label for Abilify lists tachycardia and atrial fibrillation as documented cardiac effects in overdose cases, but does not specifically mention SVT 1. The label states that "other clinically important signs and symptoms observed in one or more patients with ABILIFY overdoses include...atrial fibrillation, bradycardia...hypertension, hypotension...QRS complex prolonged, QT prolonged...status epilepticus, and tachycardia" 1.
Evidence of Arrhythmias with Aripiprazole
Documented Arrhythmias:
- Atrial fibrillation has been reported with therapeutic doses of aripiprazole, particularly in patients with concomitant risk factors (hypertension, cardiac dysfunction, rapid titration, high doses) 2
- Severe arrhythmias have been documented in case reports, including a 13-year-old with schizophrenia who developed severe arrhythmia on aripiprazole 3
- QRS widening can occur in overdose, particularly in CYP2D6 poor metabolizers, though this is distinct from SVT 4
QT Effects:
Low-quality evidence suggests that aripiprazole at therapeutic doses does not increase QT interval 5, which distinguishes it from some other antipsychotics that carry higher arrhythmia risk.
Clinical Context
Interestingly, one case report describes aripiprazole being used successfully to treat an adolescent who developed SVT while on olanzapine 6. This suggests aripiprazole may have a more favorable cardiac profile compared to some other antipsychotics.
Risk Factors for Cardiac Events
When cardiac arrhythmias do occur with aripiprazole, they are associated with:
- Overdose situations (particularly massive overdoses in children causing prolonged effects) 7
- Rapid titration and high doses 2
- CYP2D6 poor metabolizer status (approximately 8% of Caucasians, 3-8% of Black/African Americans) 1, 4
- Concomitant cardiac risk factors (hypertension, cardiac dysfunction, family history) 2
Clinical Recommendations
If a patient on aripiprazole develops palpitations or suspected arrhythmia:
- Obtain an ECG immediately to characterize the rhythm
- Look for QRS widening, QT prolongation, or specific arrhythmias (atrial fibrillation more likely than SVT)
- Consider CYP2D6 metabolizer status if toxicity is suspected
- Discontinue aripiprazole if temporally related to cardiac symptoms
- Manage any documented SVT per standard protocols (vagal maneuvers, adenosine) 8, 9
Bottom line: While aripiprazole can cause tachycardia and atrial fibrillation, SVT is not a documented adverse effect in the FDA labeling or major case series. If SVT occurs in a patient on aripiprazole, consider alternative etiologies first.